GENVOYA (by Gilead) is 4 medicines in 1 pill. It is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. it is a single-tablet regimen for HIV. It contains three different types of HIV drugs: two nucleotide/nucleoside reverse transcriptase inhibitors and one integrase inhibitor. It also contains a pharmacokinetic enhancer, a drug that has no activity against HIV, but boosts the blood levels and effectiveness of other drugs. Genvoya was approved by the U.S. Food and Drug Administration in November 2015, for use by people living with HIV who are 12 years of age or older and who are either starting HIV treatment for the first time or those wishing to switch their current regimens (provided that they have been on a stable regimen for at least six months, have an undetectable viral load and no history of HIV treatment failure or resistance to any of the drugs in Genvoya).
